Deals Of The Week: Teva/Xenon, Biogen Idec/Isis, Bristol-Myers Squibb/The Medicines Company
Executive Summary
Amgen’s unexpected buyout of deCode Genetics means the founder’s expensive philosophy of focusing on pioneering science rather than quick-to-market products finally will pay off for the Icelandic firm’s venture capital backers.